Yesterday‘s PR was huge. I think many on this board understand how significant this reduction in circulating tumor cells was. But I don’t feel like people just starting to understand CytoDyn realize what this means. Our first human data is supporting the mouse trial of 98% reduction in metastasis of cancer. If this works in triple negative breast cancer it will work in many other metastatic cancers because the mechanism of action is the same the CCR5 receptor in the micro environment around the tumor. This market is huge and we have not licensed it yet. Nader may set unrealistic timelines and self-imposed deadlines but the one thing I feel like he’s a genius at is not licensing out all indications and keeping cancer hundred percent revenue for Cytodyn.